-The Guardian Farms processing insects for animal feed might soon become global reality as demand grows for sustainable feed sources   The best way to feed the 9 billion people expected to be alive by 2050 could be to rear billions of common houseflies on a diet of human faeces and abattoir blood and grind them up to use as animal feed, a UN report published on Monday suggests. Doing so would...

-The Hindu The economic vulnerabilities that confront households in the current sluggish recovery from the global meltdown are aggravating the fight against child labour, says the International Labour Organisation. Its latest report emphasises the need for universal coverage of at least a minimum level of social security to help some 215 million working children. Half that number is trapped in the worst forms of child labour - work akin to...

-The Hindu Business Line From maker of versions of drugs, India's pharmaceutical industry has turned a top innovator Twenty years ago, Ranbaxy was a home-spun drug-maker. The Indian Patents Act allowed companies to make chemically-similar versions of innovative drugs. Visionaries in the pharmaceutical sector, like Parvinder Singh (Ranbaxy's key architect and member of its promoter family) and Anji Reddy (founder of Dr Reddy's Laboratories), were alive. And the pharmaceutical industry did not have...

-Frontline   The Supreme Court's ruling against Novartis' patent claim for the cancer drug Glivec paves the way for generic drug companies to keep crucial, life-saving drugs affordable to the common people. By V. VENKATESAN IN their 112-page judgment delivered on April 1, Justice Aftab Alam and Justice Ranjana Prakash Desai of the Supreme Court began with a simple proposition: in order to understand what the law really is, it is essential to...

-The Hindu The Supreme Court judgment on Glivec is a blow for a patent regime with a higher threshold of inventiveness On April 1, 2013, the Supreme Court upheld the Intellectual Property Appellate Board's decision to deny patent protection to Novartis's application covering a beta crystalline form of imatinib -the medicine Novartis brands as Glivec, and which is very effective against the form of cancer known as chronic myeloid leukaemia (CML). The...